GILD241227C92000
- 2.05
- 0.000.00%
Gilead Sciences Newsroom
Gilead in Pact for Anti-inflammatory Drugs in a Deal Worth up to $1.7B
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Express News | Gilead - Transaction With Leo Pharma Is Expected to Reduce Gilead’s Gaap and Non-Gaap 2025 EPS by Approximately $0.15 - $0.17
Express News | Gilead - Leo Pharma Is Eligible to Receive up to $1.7 Billion in Total Payments, Including an Upfront Payment of $250 Million
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Weekly Buzz: CES Came and Brought the Pain? That's Unexpected
Wall Street Today: Labor Gains Hurt a Hurting Market
Gilead Upgraded by Morgan Stanley on Lenacapavir Potential
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating
First Earnings Show Beats are Back, December Jobs Climbed but Market Falls Friday | Live Stock
Today's Analyst Rating | Deutsche Bank Upgrades Boston Scientific to Buy, Morgan Stanley Upgrades Gilead Sciences to Buy
Gilead Sciences Analyst Ratings
Express News | Gilead Sciences Inc. : Morgan Stanley Raises to Overweight From Equal-Weight
Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference